Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging
(MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate.
The administration of contrast agents that contain gadolinium such as Gadovist might increase
a potential risk to develop a rare condition called nephrogenic systemic fibrosis (NSF) in
patients with renal impairment. This study is to assess the potential risk to develop NSF in
patients with renal impairment after the administration of Gadovist. Patients who are
enrolled in this study will receive a Gadovist enhanced MRI scan which was prescribed by the
referring doctor. After the MRI scan the patient will be included in a two year follow-up
period to assess if signs or symptoms suggestive of NSF have appeared.